 Favourable results for levetiracetam. The treatment resulted in 69% of dogs having > 50% reduction in seizure frequency whilst 15% of all the dogs were completely free from seizures.
 Seizure frequency reduced significantly in the whole population.
 Levetiracetam pulse might be a treatment for cluster seizures.
Limitations: Retrospective case series but mainly good follow up time 1.1 years (median).
Rundfeldt (2015)
Population: Dogs with idiopathic epilepsy. (Tier I-II).
Sample size: 120 dogs, n=120
Intervention details: 2 treatment groups (including the control group)
Blinded part: Study design: Blinded, randomised, controlled clinical trial (first phase) with an open-labelled follow-up (second phase).
Outcome Studied: Objective:
To support the antiepileptic activity and safety of imepitoin in dogs with idiopathic epilepsy.
Main Findings (relevant to PICO question):
 Administration of imepitoin twice daily at a dose of 30 mg/kg results in significant and persistent antiepileptic effects in patients with newly diagnosed epilepsy suffering from generalized tonic-clonic seizures compared to 'pseudoplacebo' control group (1 mg/kg BID) of the same drug.  The safety profile of imepitoin was good, and mostly CNS related ARs were transient and predominantly observed in the first weeks of treatment.
Limitations:
 Short follow up time for first phase of study (12 weeks) .
 Open-labelled phase was an additional 12 weeks.
 A few cases had Tier I confidence level for the diagnosis of idiopathic epilepsy.
Tipold (2015)
Population: Dogs with idiopathic epilepsy (Tier I). Outcome Studied: Objective: Evaluation of the antiepileptic action of imepitoin and phenobarbital based mainly on the seizure frequency change during specific treatment period.
Main Findings (relevant to PICO question):
 The majority of the dogs were managed successfully with imepitoin.
 The same study confirmed non-inferiority of imepitoin to phenobarbital.
Limitations:
 Statistical analysis was conducted before unblinding only on the per-protocol population and not on the intent-to-treat population.
 Tier I confidence level for the diagnosis of idiopathic epilepsy.
Charalambous (2014)
Population: Dogs with idiopathic epilepsy.
Sample size: 1153 dogs, n= 1153
Intervention details: Studies were grouped based on the antiepileptic drugs they evaluated and their overall quality of evidence. Details of drug's doses, treatment period, pre-and post-treatment seizure frequency, 95% confidence interval of the successfully (≥50% reduction in seizure frequency) study population were provided.
Study design: Systematic Review.
Outcome Studied: Objective: Individual studies were evaluated based on the quality of evidence (study design, study group sizes, diagnostic procedures for enrolling dogs with idiopathic epilepsy and overall risk of bias) and the outcome measures reported (in particular the proportion of dogs with ≥50%reduction in seizure frequency).
Main Findings (relevant to PICO question):
 Overall risk of bias was moderate/high to high in 85% of the studies included.
 The diagnostic investigation procedures were poorly defined or unclear in 50% of the studies.
 Small population of dogs (<20) included in 77% of the studies.
 Oral phenobarbital and imepitoin in particular, as well as potassium bromide and levetiracetam are likely to be effective for the treatment of IE.
Limitations:
 The review was an in depth and objective assessment of the drugs' efficacy and studies' quality of evidence. Therefore, the limitations occurred in this review, derived from the studies included and evaluated in this review.  Precisely: the overall low quality of evidence; the variations in baseline characteristics of the dogs involved; the significant differences between study designs, and several potential sources of bias that were identified preclude definitive recommendations.
 The main limitation of this review is that it did not have free full access to unpublished data (e.g. EMEA report).
Fredsø (2014)
Population: Dogs with idiopathic epilepsy (Tier I or insufficient level of confidence) and structural epilepsy.
Sample size: 102 dogs, n=102
Intervention details:  One hundred and two client owned dogs; 78 dogs with idiopathic epilepsy and 24 dogs with epilepsy associated with a known intracranial cause.
 A retrospective hospital based study with follow-up. Dogs diagnosed with epilepsy between 2002 and 2008 were enrolled in the study.
 Owners were interviewed by telephone using a structured questionnaire addressing epilepsy status, treatment, death/alive, and cause of death.
Study design: Retrospective case series. Questionnaire.
Outcome Studied: Objective: To investigate risk factors for survival and duration of survival in a population of dogs with idiopathic epilepsy or epilepsy associated with a known intracranial cause.
Main Findings (relevant to PICO question):
In dogs where monotherapy was not sufficient, the need for treatment with two AED's is not linked to a poor prognosis.
Limitations:
 Retrospective case series -questionnaire.
 Insufficient or Tier I confidence level for diagnosing idiopathic epilepsy.
Packer (2014)
Population: Dogs with idiopathic epilepsy (Tier II).
Sample size: 344 dogs, n=344
Intervention details: Data from dogs was retrospectively collected from electronic patient records. Clinical data was originally gained via standardised owner questionnaires for epilepsy patients at their first appointment, and longitudinal follow up data was gained via telephone interview with the dogs' owners. Study design: Retrospective case series.
Outcome Studied: Objective: To identify clinical risk factors associated with antiepileptic drug responsiveness in canine epilepsy.
Main Findings (relevant to PICO question):
The presence of cluster seizures and thus seizure density is a more influential risk factor on the likelihood of achieving remission in canine epilepsy than seizure frequency or the total number of seizures prior to treatment.
Limitations:
 Retrospective case series study.
 However, thorough statistics were used which were good in filtering out the non-significant.
Kiviranta (2013)
Population: Dogs with idiopathic epilepsy (Tier I).
Sample size: 10 dogs, n=10 Outcome Studied: Objective: Evaluation of the antiepileptic action of topiramate based mainly on the seizure frequency change during specific treatment period.
Main Findings (relevant to PICO question):
 Favourable results for topiramate adjunctive therapy.
 Approximately half of the study population had ≥50% reduction in seizure frequency.
Limitations:
 Non-blinded, non-randomised and uncontrolled trial.
 Low study population.
 Precise doses of concurrent AEDs were not reported. Outcome Studied: Objective: Evaluation of the antiepileptic action of potassium bromide based mainly on the seizure frequency change during specific treatment period.
Main Findings (relevant to PICO question):
Favourable results for potassium bromide adjunctive therapy in all dogs.
Limitations:
 Only abstract was retrieved. Low study population.
 Insufficient confidence level for the diagnosis of idiopathic epilepsy. Precise reduction in seizure frequency could not be detected only based on the abstract.
 Non-blinded, non-randomized, uncontrolled trial.
Boothe (2012)
Population: Dogs with idiopathic epilepsy (Tier I). Study design: Blinded, randomised, controlled clinical trial.
Outcome Studied: Objective: Evaluation of the antiepileptic action of phenobarbital in comparison to potassium bromide based mainly on the seizure frequency change during specific treatment period.
Main Findings (relevant to PICO question):
 Favourable results for phenobarbital and potassium bromide monotherapy.
 The majority of the study population had ≥50% reduction in seizure frequency in both groups. The percentage of successfully treated cases was higher in phenobarbital group.
 Phenobarbital treated dogs had less side effects than potassium bromide dogs.
Limitations:
Tier I confidence level for diagnosing idiopathic epilepsy.
Chung (2012)
Sample size: 10 dogs, n=10 Outcome Studied: Objective: Evaluation of the antiepileptic action of zonisamide based mainly on the seizure frequency change during specific treatment period.
Main Findings (relevant to PICO question):
Favourable results for zonisamide monotherapy. Approximately half of the study population had ≥50% reduction in seizure frequency.
Limitations:
 Research support but unclear if it was financial.
Kis (2012)
Population: Dogs with idiopathic epilepsy (Tier I). 
Main Findings (relevant to PICO question):
 In the investigated population 25 patients (36%) had measured concentration of phenobarbital under the lower therapeutic limit with adequate control of seizures.
 Only in 16% phenobarbital was ineffective in eradication of seizures.
 Phenobarbital is reasonable first-choice antiepileptic drug for treatment of canine idiopathic epilepsy in Croatia.
Limitations:
 Conference abstract.
 Retrospective case series (high risk of bias).
 Tier I confidence level for diagnosing idiopathic epilepsy.
Matthews (2012)
Population: Dogs with idiopathic epilepsy (insufficient level of confidence). Twelve weeks of treatment with fatty acid supplementation, followed by a 12-week placebo period of olive oil supplementation.
Study design: Blinded, placebo-controlled, clinical trial.
Outcome Studied: Objective: Evaluation of the effect of fatty acid supplementation based mainly on the seizure frequency change during specific treatment period.
Main Findings (relevant to PICO question):
Fatty acid supplementation did not reduce seizure frequency or severity in dogs with idiopathic epilepsy.
Limitations:
 Non-randomised. Study design: Blinded, randomised, placebo-controlled clinical trial.
Outcome Studied: Objective: Evaluation of the antiepileptic action of levetiracetam based mainly on the seizure frequency change during specific treatment period and compared to the placebo group.
Main Findings (relevant to PICO question):
 Favourable results for levetiracetam adjunctive therapy.
 The majority of the study population had ≥50% reduction in seizure frequency.
 The latter was reduced significantly compared to baseline but no difference was detected when compared to the placebo group (dogs in both the placebo and levetiracetam group were on maintenance therapy with phenobarbital and/or potassium bromide and/or gabapentin).
Limitations:
 Potential risk of comparing to retrospective baseline. the results.
 The study had financial support but unclear if it influenced
Jambroszyk (2011)
Population: Dogs with idiopathic epilepsy (Tier I-II).
Sample size: 6 dogs, n=6
Intervention details: 1 Treatment group, no Control group.
Treatment group:
Drug: Verapamil as an adjunct to phenobarbital Study design: Uncontrolled clinical trial.
Outcome Studied: Objective: Evaluation of the antiepileptic action of verapamil based mainly on the seizure frequency change during specific treatment period.
Main Findings (relevant to PICO question):
Failure of the maximum tolerated dose to improve seizure control.
Limitations:
 Tier I confidence level for diagnosing idiopathic epilepsy for some cases.
Gaskill (2010)
Population: Dogs with idiopathic epilepsy (insufficient level of confidence).
Sample size: 62 dogs, n=62
Intervention details: 2 comparison treatment groups. Phenobarbital (n=30) and potassium bromide (n=32) were compared as monotherapies for 12 months. Details of doses are not given.
Study design:
Open-labeled, randomised, controlled trial.
Outcome Studied: Objective: To compare phenobarbital to potassium bromide monotherapy.
Main Findings (relevant to PICO question):
Phenobarbital was more effective and better tolerated than potassium bromide monotherapy. 
Limitations:
 Conference paper.
 Non-blinded and non-randomised. Insufficient confidence level for diagnosing idiopathic epilepsy.
Dewey (2009)

Population: Dogs with idiopathic epilepsy (Tier I-II).
Sample size: 9 dogs, n=9
Treatment group:
Drug: pregabalin as an adjunct to phenobarbital and potassium bromide Dose: pregabalin: 2 mg/kg PO TID (dose was increased up to until 3-4 mg/kg PO TID); doses of other AEDs were not available but reported to be within normal reference values
Treatment period: 3 months n= 9
Study design: Uncontrolled clinical trial.
Outcome Studied: Objective: Evaluation of the antiepileptic action of pregabalin based mainly on the seizure frequency change during specific treatment period.
Main Findings (relevant to PICO question):
 Favourable results for pregabalin adjunctive therapy.
Limitations:
 Non-blinded, non-randomised and uncontrolled trial  Low study population.
 Short follow up -3 months study duration.
 Precise doses of concurrent AEDs were not reported.
Scorza (2009)
Population: Dog with idiopathic epilepsy (insufficient level of confidence).
Sample size: 1 dog, n=1
Intervention details: 1 case.
Supplement the dog's diet with moderate amounts of fish oil (oral omega-3 polyunsaturated fatty acids, 2 g/day). Phenobarbital (2.5 mg/kg, twice a day orally) Study design: Case report.
Outcome Studied: Subjective: To evaluate the effectiveness of daily intake of a moderate amount of fish oil in a case of canine epilepsy.
Main Findings (relevant to PICO question):
 The frequency of the epileptic seizures markedly fell after 50 days of combination therapy with phenobarbital and omega-3 fatty acid.
 During the subsequent 18-month period, seizure frequency fell to one per 3 months, a reduction of about 85%.
Limitations:
 Case report (high risk of bias).  Insufficient confidence level for diagnosing idiopathic epilepsy.  Insufficient details on the type of fish oil used or specific concentrations.
Volk (2009)
Population: Dogs with idiopathic epilepsy (Tier II level of confidence).
Sample size: 22 dogs, n=22
Intervention details: 1 Treatment group, no Control group. total pages: 38 treatment period.
Main Findings (relevant to PICO question):
 The majority of the study population had ≥50% reduction in seizure frequency in both, clinical trial and case series part.
Limitations:
 The study had financial support but unclear if it influenced the results.  Part of the study was retrospective.  Precise doses of concurrent AEDs were not reported; but phenobarbital and potassium bromide serum levels were reported.
Musteata (2007)
Population: Dogs with idiopathic epilepsy(insufficient level of confidence).
Sample size: 11 dogs, n=11
Treatment group:
Drug: gabapentin as an adjunct to phenobarbital Outcome Studied: Objective: Evaluation of the antiepileptic action of gabapentin based mainly on the seizure frequency change during specific treatment period.
Main Findings (relevant to PICO question):
 Favourable results for gabapentin as adjunctive therapy.  Significant reduction in frequency of epileptic attacks (67.29+or-9.03%) in the majority of the dogs (7 patients) (63.63%) allowing a progressive reduction in the PB doses to 5 mg/kg PO BID.
Limitations:
 Non-blinded, non-randomised, uncontrolled trial.
 Insufficient confidence level for diagnosing idiopathic epilepsy. Outcome Studied: Objective: Evaluation of the antiepileptic action of belladonna and cocculus based mainly on the seizure frequency change during specific treatment period.
Main Findings (relevant to PICO question):
Seizure-free status was achieved during the treatment period, but 20% of the dogs had again seizures 15-25 days after Belladona stopped. Then, it was restarted for 2-3 months until seizures were ceased.
Limitations:
 Controversial results.  Unclear/Insufficient confidence level for diagnosing idiopathic epilepsy.
Von Klopmann (2007)
Population: Dogs with idiopathic epilepsy (Tier I-II level of confidence).
Sample size: 11 dogs, n=11
Treatment group:
Drug: zonisamide as an adjunct to phenobarbital and/or potassium bromide period.
Main Findings (relevant to PICO question):
 Favourable results for zonisamide adjunctive therapy.
Limitations:
Platt (2006)
Population: Dogs with idiopathic epilepsy (Tier I level of confidence).
Sample size: 11 dogs, n=11
Treatment group:
Drug: gabapentin as an adjunct to phenobarbital and potassium bromide Outcome Studied: Objective: Evaluation of the antiepileptic action of gabapentin based mainly on the seizure frequency change during specific treatment period.
Main Findings (relevant to PICO question):
 Favourable results for gabapentin adjunctive therapy.
Limitations:
 Less than 6 months study duration. Precise doses of concurrent AEDs were not reported.
 Tier I confidence level for diagnosing idiopathic epilepsy. bromide adjunctive treatment based mainly on the seizure frequency change during specific treatment period.
Main Findings (relevant to PICO question):
 Only less than the half of the study population had ≥50% reduction in seizure frequency with imepitoin monotherapy, imepitoin adjunctive therapy and potassium bromide adjunctive therapy.
 The majority of the study population had ≥50% reduction in seizure frequency with phenobarbital and primidone monotherapy.
Limitations:
 Part of the study was retrospective.
Govendir (2005)
Sample size: 17 dogs, n=17
Treatment group:
Drug: gabapentin as an adjunct to phenobarbital and/or potassium bromide Outcome Studied: Objective: Evaluation of the antiepileptic action of gabapentin based mainly on the seizure frequency change during specific treatment period.
Main Findings (relevant to PICO question):
 Approximately more than the half of the study population had ≥50% reduction in seizure frequency.
Limitations:
 A few cases were treated by the referring vets.
 The study had financial support.
 Tier I confidence level for diagnosing idiopathic epilepsy for some cases. Outcome Studied: Objective: Evaluation of the ketogenic food effectiveness in the seizure control based mainly on the seizure frequency change during specific treatment period.
Main Findings (relevant to PICO question):
 Only 33% of the study population had ≥50% reduction in seizure frequency.  No difference between two groups.
Limitations:
 Doses/quantity of food or AEDs are not mentioned.
 Needed 22 dogs per group based on power calculation; thus, insufficient power in this study.
 Insufficient confidence level for diagnosing idiopathic epilepsy.
Dewey (2004)
Sample size: 12 dogs, n=12
Treatment group:
Drug: zonisamide as an adjunct to phenobarbital and/or potassium bromide Outcome Studied: Objective: Evaluation of the antiepileptic action of zonisamide based mainly on the seizure frequency change during specific treatment period.
Main Findings (relevant to PICO question):
 Favourable results for zonismide adjunctive therapy.  Approximately half of the study population had ≥50% reduction in seizure frequency.
Limitations:
 Short follow-up period.
Steinberg (2004)
Population: Dogs with idiopathic epilepsy (insufficient level of confidence).
Sample size: 15 dogs, n=15
Treatment group:
Drug: levetiracetam as an adjunct to phenobarbital and potassium bromide Outcome Studied: Objective: Evaluation of the antiepileptic action of levetiracetam based mainly on the seizure frequency change during specific treatment period.
Main Findings (relevant to PICO question):
 Favourable results for levetiracetam adjunctive therapy.  All the dogs of the study population had ≥50% reduction in seizure frequency. Limitations:  Low study population.
Muñana (2002)
Population: Dogs with idiopathic epilepsy (Tier II confidence level).
Sample size: 10 dogs, n=10
Intervention details: 1 Treatment group, 1 Control group.
Treatment group:
Vagal nerve stimulation adjunctive to phenobarbital and/or potassium bromide and/or felbamate
Control Group:
No device
Method: 13 weeks of treatment followed (after 4 weeks wash-out) by 13 weeks of control (inactive device)
Study design: Double blinded crossover controlled clinical trial
Outcome Studied: Objective: To investigate the antiepileptic efficacy of vagal nerve stimulation.
Main Findings (relevant to PICO question):
Mean decrease in seizure frequency between the 2 groups was 5.1% and not significant.
Limitations:
 Assessment bias in favor of the device introduced by owners' assessment could be a possibility.
Ruehlmann (2001)
Sample size: 6 dogs, n=6
Treatment group:
Drug: felbamate as an adjunct to phenobarbital 
Main Findings (relevant to PICO question):
 Favourable results for felbamate adjunctive therapy.  All the dogs of the study population had ≥50% reduction in seizure frequency.
Limitations:
 Part of the study was retrospective. No clarification of statistical analysis.
Trepanier (1998)
Sample size: 122 dogs, n=122
Treatment group:
Drug: potassium bromide as an adjunct to phenobarbital or primidone Dose: Doses were not available but adjusted according to the therapeutic serum levels and clinical response Study design: Retrospective case series study.
Outcome Studied: Objective: Evaluation of the antiepileptic action of potassium bromide as adjunctive therapy based mainly on the seizure frequency change during specific treatment period.
Main Findings (relevant to PICO question):
 Favourable results for potassium bromide adjunctive therapy.  The majority of the study population had ≥50% reduction in seizure frequency.
Limitations:
 Retrospective nature of study.
 Insufficient confidence level for diagnosing idiopathic epilepsy. Study design: Retrospective case series study.
Outcome Studied: Objective: Evaluation of the antiepileptic action of phenobarbital based mainly on the seizure frequency change during specific treatment period.
Main Findings (relevant to PICO question):
 Favourable results for phenobarbital monotherapy.
Limitations:
 Less than 6 months study duration.
 The study had financial support but unclear if it influenced the results.
O'Brien (1997)
Sample size: 10 dogs, n=10
Treatment group:
Drug: nimodipine as an adjunct to phenobarbital or primidone. Study design: Uncontrolled clinical trial.
Outcome Studied: Objective: Evaluation of the antiepileptic action of nimodipine as adjunctive therapy based mainly on the seizure frequency change during specific treatment period.
Main Findings (relevant to PICO question):
Nimodipine was not successful in controlling seizures in dogs.
Limitations:
Podell (1993)
Population: Dogs with idiopathic epilepsy (Tier I-II level of confidence)
Sample size: 37 dogs, n=37
Treatment group:
Drug: potassium bromide as an adjunct to phenobarbital Study design: Retrospective case series study.
Main Findings (relevant to PICO question):
 Favourable results for potassium bromide adjunctive therapy.
Limitations:
 Retrospective case series.
Schwartz-Porsche (1991)
Population: Dogs with idiopathic epilepsy (Tier II level of confidence). Outcome Studied: Objective: Evaluation of the antiepileptic action of potassium bromide as adjunctive therapy based mainly on the seizure frequency change during specific treatment period.
Main Findings (relevant to PICO question):
 Favourable results for potassium bromide adjunctive therapy.  More than half of the study population had ≥50% reduction in seizure frequency.
Limitations: Non-blinded, non-randomised and uncontrolled trial.
Pearce (1990)
Sample size: 10 dogs, n=10
Treatment group:
Drug: potassium bromide as an adjunct to phenobarbital Dose: potassium bromide: 22 PO SID (dose increases occurred); phenobarbital: median 3.3 mg/kg, mean 3.8 mg/kg PO BID (dose was reduced by a mean of 50% in 7/10 dogs during the PBr treatment)
Treatment period: median 7, mean 7.8 months n=10
Main Findings (relevant to PICO question):
 Favourable results for potassium bromide adjunctive therapy.  The majority of the study population had ≥50% reduction in seizure frequency. Limitations:  Non-blinded, non-randomised and uncontrolled trial.
Morton (1988)
Sample size: 19 dogs, n=19
Intervention details: 2 treatment groups
Treatment group 1:
Drug: Phenobarbital Outcome Studied: Objective: Evaluation of the antiepileptic action of primidone and phenobarbital monotherapy based mainly on the seizure frequency change during specific treatment period.
Main Findings (relevant to PICO question):
 Favourable results for primidone and phenobarbital monotherapy  The majority of the study population had ≥50% reduction in seizure frequency in primidone group.
 Approximately half of the study population had ≥50% reduction in seizure frequency in phenobarbital group.
Limitations:
 The study had financial support but unclear if it influenced the results. Insufficient confidence level for diagnosing idiopathic epilepsy. Study design: Open-labeled, randomized, controlled clinical trial.
Outcome Studied: Objective: Evaluation of the antiepileptic action of primidone and phenobarbital monotherapy based mainly on the seizure frequency change during specific treatment period.
Main Findings (relevant to PICO question):
 Favourable results for phenobarbital and primidonemonotherapy.
Limitations:
 Non-blinded.
 The study had research support but unclear if it influenced the results.
 No clarification of statistical analysis. Insufficient confidence level for diagnosing idiopathic epilepsy.
Cunningham (1983)
Sample size: 15 dogs, n=15
Intervention details: 1 Treatment group, no Control group. Outcome Studied: Objective: Evaluation of the antiepileptic action of primidonebased mainly on the seizure frequency change during specific treatment period.
Main Findings (relevant to PICO question):
 Favourable results for primidone monotherapy.  The majority of the study population had ≥50% reduction in seizure frequency.
Limitations:
Schwartz-Porsche et al. (1982)
Sample size: 30 dogs, n=30
Treatment group:
Drug: primidone Outcome Studied: Objective: Evaluation of the antiepileptic action of primidone based mainly on the seizure frequency change during specific treatment period.
Main Findings (relevant to PICO question):
 Favourable results for primidone monotherapy.
Limitations: Non-blinded, non-randomised and uncontrolled trial. Outcome Studied: Objective: Evaluation of the antiepileptic action of sodium valproate as adjunctive therapy or monotherapy based mainly on the seizure frequency change during specific treatment period.
 The majority of the study population did not have ≥50% reduction in seizure frequency in groups 1,2 and 4.  In group 3, approximately half of the study population had ≥50% reduction in seizure frequency.
Limitations:
 No seizure-free dogs.
 Tier I confidence level for diagnosing idiopathic epilepsy for some cases * The level of confidence for diagnosing idiopathic epilepsy (Tier I-III) used in this knowledge summary was based on the international veterinary epilepsy task force (IVETF) consensus statement on the diagnosis of idiopathic epilepsy (De Risio, L. et al. 2015). Any paper that included dogs with idiopathic epilepsy for which diagnostic investigations were below this Tier level of evidence or unclear was considered to provide insufficient level of confidence for diagnosing idiopathic epilepsy. Tier I was listed in the limitations of the papers as this could indicate that a few dogs might have suffered from structured epilepsy and as a result have not responded adequately or at all to the treatment.
Appraisal, application and reflection
Various antiepileptic drugs (AEDs) are used for the management of canine idiopathic epilepsy. Although individual assumptions for AEDs' efficacy could be made based on the studies' results and the level of evidence provided, direct comparisons of efficacy between AEDs were limited due to lack of controlled studies. Precisely, based on the controlled studies, direct AED comparisons include: Tipold et al. (2014) showed that monotherapy with imepitoin in dogs with newly diagnosed epilepsy was almost similarly effective and potentially more tolerated than phenobarbital. The same result was reported within other studies investigated in the systematic review by Charalambous et al. (2014) .
Phenobarbital vs Imepitoin
Phenobarbital vs Potassium bromide
Bootheet al. (2012) and Gaskill and Kimber (2010) found that phenobarbital was more effective and better tolerated than potassium bromide monotherapy. Phenobarbital vs Primidone Schwartz-Porsche et al. (1985) reported that the difference between the efficacy of phenobarbital and primidone was not significant, but primidone caused signs of liver toxicity in 70% of the dogs in the group.
Primidone vs Imepitoin
In a US field study, as reported in the EMEA (2012) report, imepitoin failed to demonstrate higher efficacy compared to primidone. However, this study was considered only as supportive information because the control group therapy (primidone) is not approved in Europe.
Finally, Muñana et al. (2012) compared levetiracetam to placebo and found that seizure frequency was reduced significantly compared to baseline but no difference was detected when compared to the placebo group. Direct comparisons between other AEDs could not be performed based on the current published evidence. Generally, AED monotherapy or adjunctive therapy with multiple drugs can be chosen according to the clinically successful control of seizures (i.e. usually >50% or, ideally, 100% reduction in seizure frequency) and side effects. Fredsø et al. (2014) reported that in dogs where monotherapy was not sufficient, the need for treatment with two AEDs has not been linked to a reduced survival. Packer et al. (2015) demonstrated that 37.5% of dogs that received a third-line AED after treatment failure with two AEDs were responsive to this drug (achieving > 50% reduction in seizure frequency). The same study found that only dogs that responded to the first AED became seizure-free. Lastly, Packer et al. (2014) found that the presence of cluster seizures and thus seizure density is a more influential risk factor on the likelihood of achieving remission in canine epilepsy than seizure frequency or the total number of seizures prior to treatment.
Alternative therapies have been also investigated for treating canine epilepsy (including diet trials, nerve stimulation, homeopathic agents), but the results were not very encouraging based on these. Munana et al. At this point it is worth mentioning that the international veterinary epilepsy task force (IVETF) recently published a consensus statement (Bhatti et al. 2015) for treatment suggestions based mainly on current published evidence as provided and analyzed in this knowledge summary and in the systematic review by Charalambous et al. (2014) and it was additionally supported and adjusted by expert's opinions.
Implications for the future: Generally, several potential sources of bias and limitations were identified in the studies. Many of the studies included dogs with poor or unclear diagnostic investigations for idiopathic epilepsy and small study population and, consequently, definite recommendations are precluded. Therefore, further bRCTs are needed mainly for the AEDs, such as zonisamide, for which there are no high quality studies to support their favourable efficacy. Lastly, further and stronger evidence is vital for imepitoin as a new licensed drug in Europe before definite recommendation on its efficacy and tolerability are drawn.
Limitation of the summary:
The main limitation of this summary is that we could not obtain full access to a few papers included in the summary of evidence. 
